Cagrilintide | Luxbae Peptide Therapy

Home › Peptides › Cagrilintide
Long-Acting Amylin Analogue

Cagrilintide Amylin Analogue

A long-acting amylin analogue studied in combination with semaglutide for enhanced weight loss.

Book Free ConsultationCall 310.299.4444

What Cagrilintide actually is

Cagrilintide is a long-acting analogue of amylin — the pancreatic beta-cell co-secreted hormone that contributes to satiety, slows gastric emptying, and inhibits postprandial glucagon. The phase 2 program demonstrated additive weight loss when combined with semaglutide as CagriSema.1

REDEFINE trial readouts from Novo Nordisk’s CagriSema (cagrilintide + semaglutide) program show weight loss in the high teens to low twenties on combined therapy.2 At Luxbae we prescribe cagrilintide as an adjunct layer for patients plateauing on GLP-1 monotherapy.

At Luxbae, Cagrilintide is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.

Mechanism — Amylin receptor and calcitonin

Activates amylin receptors (AMY1, AMY3); slows gastric emptying, increases satiety, suppresses glucagon — complementary to GLP-1.3

What the research shows

Additive weight loss. Combined with semaglutide produces greater loss than either alone.1

Satiety enhancement. Amylin’s satiety pathway differs from GLP-1; patients report different fullness signal.

Glycemic effect. Postprandial glucagon suppression contributes to glycemic stability.

Side effects: GI symptoms (similar to GLP-1), nausea, occasional vomiting during titration, fatigue.

FDA note: Cagrilintide is not yet FDA-approved. CagriSema is in late-stage development (Novo Nordisk).

Cagrilintide FAQ

Is this approved?
Not yet — CagriSema is in late-stage trials. Compounded use is investigational.

Better than semaglutide alone?
Trial data shows additive effect when combined with semaglutide.

References

  1. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg. Lancet. 2021;397(10286):1736-1748.
  2. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with semaglutide. Lancet. 2023.
  3. Hay DL, Chen S, Lutz TA, et al. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol Rev. 2015;67(3):564-600.

Start your Cagrilintide protocol at Luxbae

Call 310.299.4444Book Online
Medical disclaimer: This is educational information, not medical advice. Cagrilintide is investigational and many uses are not FDA-approved; treatments at Luxbae are administered under medical supervision by Dr. Ernst von Schwarz. Individual results vary.
Scroll to Top